We also explored the efficiency of the murine HER2-targeted antibody modified to deliver the α-particle emitter 225Ac compared to the β-particle emitter 90Y, and found that 225Ac-labeled antibody significantly extended the survival in the neu-N mice with metastatic disease [4]. Here, ERBB2 is linked to metastatic neoplasm.